Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib Plus Trastuzumab Deruxtecan in KRAS-Mutant, HER2-Expressing Pancreatic Cancer
NCT07619521Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2027
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib and trastuzumab deruxtecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities at day 21, HER2 expression status at 1 year and 1 more. Planned start Jun 2027; status: recruiting.
02
Drugs
selumetinibtrastuzumab deruxtecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07619521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619521.